Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Medical Care Research and Review
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schweitzer, S. O.
Right arrow Articles by Guellec, M.-J. S.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schweitzer, S. O.
Right arrow Articles by Guellec, M.-J. S.-L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Is there a U.S. Drug Lag? The Timing of New Pharmaceutical Approvals in the G-7 Countries and Switzerland

Stuart O. Schweitzer

University of California, Los Angeles

Maurice E. Schweitzer

University of Miami

Marie-Jo Sourty-Le Guellec

Centre de Recherche, d'Etude, et de Documentation en Economie de la Santé (CREDES)

To test whether the United States is slow in approving new drugs, the date of approval of 34 important pharmaceuticals approved in the United States between 1970 and 1988 were compared with those of the other G-7 countries plus Switzerland. The drugs studied in the analysis were designated as having been especially important and therapeutically significant at the time of their approval by panels of physicians and pharmacists in the United States and France. Drug lags were measured for each country for each drug by computing the number of months elapsed from the time a drug was first approved by one of the countries in this sample. Although Switzerland was found to approve drugs generally more quickly than other countries, differences between countries tended to be small. The United States was relatively fast in approving the drugs, countering the contention that it suffers from a substantial drug lag.

Medical Care Research and Review, Vol. 53, No. 2, 162-178 (1996)
DOI: 10.1177/107755879605300203


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?